Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: A randomized placebo-controlled pilot study
BACKGROUND: Data from an open-label trial suggest that mirtazapine might prove useful in treatment of fibromyalgia syndrome (FMS). OBJECTIVE: To obtain preliminary efficacy data of mirtazapine for estimation of sample size requirements for a Phase 2 clinical trial in FMS. METHODS: This 13-week rando...
Saved in:
Main Authors: | , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/32270 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.32270 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.322702018-10-19T12:21:36Z Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: A randomized placebo-controlled pilot study Suwimon Yeephu Chuthamanee Suthisisang Saithip Suttiruksa Pradit Prateepavanich Patchara Limampai Irwin Jon Russell Mahidol University University of Texas at San Antonio Medicine BACKGROUND: Data from an open-label trial suggest that mirtazapine might prove useful in treatment of fibromyalgia syndrome (FMS). OBJECTIVE: To obtain preliminary efficacy data of mirtazapine for estimation of sample size requirements for a Phase 2 clinical trial in FMS. METHODS: This 13-week randomized controlled trial compared the effects of mirtazapine 15 mg/day, mirtazapine 30 mg/day, and placebo in 40 patients with FMS. The primary outcomes were change in Pain Visual Analog Scale (PVAS) and proportion of pain responders (≥30% PVAS reduction). Secondary outcomes included scores from the Jenkins Sleep Scale (JSS), Patient Global Impression of Change (PGIC), Fibromyalgia Impact Questionnaire (FIQ), Hamilton Depression Rating Scale (HAM-D), Patient Global Assessment, and self-reported adverse events. RESULTS: Significant within-group PVAS reductions from baseline were observed in all 3 groups, with the greatest improvement in the mirtazapine 30-mg group (p < 0.005); between-group difference was not significant. The proportion of pain responders did not meet significance criteria (66.67% for mirtazapine 30 mg, 50% for mirtazapine 15 mg, 41.67% for placebo). Significant within-group improvement in JSS scores was seen for mirtazapine 30 mg (p < 0.01) and mirtazapine 15 mg (p < 0.05). Between-group comparison achieved significance for JSS item 3, waking several times per night (p < 0.05). On the PGIC, 72.73% felt better with both mirtazapine dosages compared with 50% for placebo. Withingroup FIQ responses indicated improvement in only mirtazapine-treated groups, whereas within-group improvement for HAM-D and Patient Global Assessment was observed in all groups. Based on our findings, the sample size requirement (80% power, 5% type I error) should be 83 per group to detect PVAS change difference between mirtazapine 30 mg and placebo. Common mirtazapinerelated adverse events were increased appetite and weight gain. CONCLUSIONS: Patients with FMS taking mirtazapine exhibited within-group significant improvement in most of the measured outcomes. Between-group analysis was predictably compromised by the small sample size. Mirtazapine was well tolerated. Further study with a larger sample size is likely to be useful. © 1967-2013 Harvey Whitney Books Co. All rights reserved. 2018-10-19T05:21:36Z 2018-10-19T05:21:36Z 2013-07-01 Article Annals of Pharmacotherapy. Vol.47, No.7-8 (2013), 921-932 10.1345/aph.1R725 10600280 2-s2.0-84880069235 https://repository.li.mahidol.ac.th/handle/123456789/32270 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84880069235&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Suwimon Yeephu Chuthamanee Suthisisang Saithip Suttiruksa Pradit Prateepavanich Patchara Limampai Irwin Jon Russell Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: A randomized placebo-controlled pilot study |
description |
BACKGROUND: Data from an open-label trial suggest that mirtazapine might prove useful in treatment of fibromyalgia syndrome (FMS). OBJECTIVE: To obtain preliminary efficacy data of mirtazapine for estimation of sample size requirements for a Phase 2 clinical trial in FMS. METHODS: This 13-week randomized controlled trial compared the effects of mirtazapine 15 mg/day, mirtazapine 30 mg/day, and placebo in 40 patients with FMS. The primary outcomes were change in Pain Visual Analog Scale (PVAS) and proportion of pain responders (≥30% PVAS reduction). Secondary outcomes included scores from the Jenkins Sleep Scale (JSS), Patient Global Impression of Change (PGIC), Fibromyalgia Impact Questionnaire (FIQ), Hamilton Depression Rating Scale (HAM-D), Patient Global Assessment, and self-reported adverse events. RESULTS: Significant within-group PVAS reductions from baseline were observed in all 3 groups, with the greatest improvement in the mirtazapine 30-mg group (p < 0.005); between-group difference was not significant. The proportion of pain responders did not meet significance criteria (66.67% for mirtazapine 30 mg, 50% for mirtazapine 15 mg, 41.67% for placebo). Significant within-group improvement in JSS scores was seen for mirtazapine 30 mg (p < 0.01) and mirtazapine 15 mg (p < 0.05). Between-group comparison achieved significance for JSS item 3, waking several times per night (p < 0.05). On the PGIC, 72.73% felt better with both mirtazapine dosages compared with 50% for placebo. Withingroup FIQ responses indicated improvement in only mirtazapine-treated groups, whereas within-group improvement for HAM-D and Patient Global Assessment was observed in all groups. Based on our findings, the sample size requirement (80% power, 5% type I error) should be 83 per group to detect PVAS change difference between mirtazapine 30 mg and placebo. Common mirtazapinerelated adverse events were increased appetite and weight gain. CONCLUSIONS: Patients with FMS taking mirtazapine exhibited within-group significant improvement in most of the measured outcomes. Between-group analysis was predictably compromised by the small sample size. Mirtazapine was well tolerated. Further study with a larger sample size is likely to be useful. © 1967-2013 Harvey Whitney Books Co. All rights reserved. |
author2 |
Mahidol University |
author_facet |
Mahidol University Suwimon Yeephu Chuthamanee Suthisisang Saithip Suttiruksa Pradit Prateepavanich Patchara Limampai Irwin Jon Russell |
format |
Article |
author |
Suwimon Yeephu Chuthamanee Suthisisang Saithip Suttiruksa Pradit Prateepavanich Patchara Limampai Irwin Jon Russell |
author_sort |
Suwimon Yeephu |
title |
Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: A randomized placebo-controlled pilot study |
title_short |
Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: A randomized placebo-controlled pilot study |
title_full |
Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: A randomized placebo-controlled pilot study |
title_fullStr |
Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: A randomized placebo-controlled pilot study |
title_full_unstemmed |
Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: A randomized placebo-controlled pilot study |
title_sort |
efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study |
publishDate |
2018 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/32270 |
_version_ |
1763490012592078848 |